NEW YORK ( TheStreet) -- The following 10 global pharmaceutical stocks will likely benefit from the expanding global pharmaceutical markets, which are poised to grow at 5%-7% in 2011 to $880 billion, according to IMS Health. 17 Pharmemerging markets, including China and India, are forecast to grow at 15%-17% in 2011 to $180 billion, faster than the global markets.

Analysts give these 10 stocks a 100% buy ratings. In comparison, pharma giants Johnson & Johnson ( JNJ), Pfizer ( PFE), Merck ( MRK), Abbott Laboratories ( ABT), Bristol Myers Squibb ( BMY) and Eli Lilly ( LLY) have buy ratings in the range of 8.3%-71.4%.

In addition, analysts expect these 10 stocks to outperform their peers and broader markets, based on the upside implied from their respective 12-month price targets. These stocks have an implied upside potential of 25%-147% with a mean upside value of around 91%.

With five analysts covering the stock, Aegerion Pharmaceuticals ( AEGR) has 100% buy ratings, however, we have not included the stock in our discussion since analysts expect the stock to have an upside of only 12%, much lower than the 10 stocks listed here. The other stocks that do not find a place here are AVANIR Pharmaceuticals ( AVNR), Somaxon Pharmaceuticals ( SOMX), Biostar Pharmaceuticals ( BSPM), Threshold Pharmaceuticals ( THLD), EpiCept ( EPCT), Ventrus Biosciences ( VTUS) and Repros Therapeutics ( RPRX), even though they are expected to have triple-digit upsides because only a few analysts cover these stocks.

The stocks are stacked in an ascending order based on the number of analysts covering each stock and, in case of a tie-up, by implied percentage upside.

If you liked this article you might like

3 Biotech Stocks on Readers' Minds

Trump's FDA: A Friendlier Biotech Sheriff

2 Recovering Biotech Names With Room to Run

4 Undervalued Biotech Stocks

2 Oversold Biopharmas With Big 2017 Upsides